IMTX earnings: next report 2026-08-12, real EPS beat/miss history, analyst consensus Buy, P/E -4.70. Updated 2026-07-23.
Immatics (IMTX) Research Hub
Immatics (IMTX) trades on NASDAQ, DE in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 8.79 USD (-3.51%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.70, market cap 1.23B. This hub links to the full technical, earnings and options research available for IMTX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, DE |
| Last close | 8.79 USD (-3.51%) |
| 52-week range | 8.17 USD – 10.38 USD |
| Trend regime | Range |
| 14-day RSI | 31.8 (Bearish) |
| Trailing P/E | -4.70 |
| Market cap | 1.23B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for IMTX
Covered Call on IMTX: how it works, illustrative setup around the real 8.79 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on IMTX: how it works, illustrative setup around the real 8.79 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on IMTX: how it works, illustrative setup around the real 8.79 USD price, max profit/loss, breakeven and when to use it. Educational.
IMTX technical analysis: range, last 8.79 USD, RSI 31.8, 52w range 8.17 USD–10.38 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is IMTX in?
Immatics (IMTX) is classified under Healthcare (Biotechnology), listed on NASDAQ, DE.
Is IMTX in an uptrend or downtrend?
As of 2026-09-11, IMTX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is IMTX's trailing P/E ratio?
IMTX's trailing P/E is -4.70, with a market cap of 1.23B. See the earnings research page for full valuation detail.
When does IMTX next report earnings?
IMTX is next scheduled to report earnings on 2026-08-12, with a consensus EPS estimate of -0.48439 USD.